The company will market Inivata's InVision liquid biopsy assays to insured and self-pay patients across the region.
Illumina is partnering with SV Health Investors, Sofinnova Partners, Seventure Partners, and F-Prime Capital to bring its startup incubator to Europe.
23andMe customers who have one of three common variants identified in reports can choose six family members to receive health and ancestry test kits.
EdiGene has developed a diploid library of 2,800 single clonal knockout cell lines, targeting 2,600 genes in commonly used human cancer cell lines.
Mirnax will use Arcis' nucleic acid sample preparation and preservation technology to improve the stability of miRNA biomarkers for early disease detection.
Additionally, Cancer Genetics noted that last week it sold off its clinical laboratory business to siParadigm, a specialty reference laboratory, for about $1 million.
A federal judge upheld a $24 million jury award to Bio-Rad, while a trade court judge said Bio-Rad imported microfluidics that infringed 10x patents.
The Forbes' Quarry Neanderthal from Gibraltar is genetically more similar to older specimens than to younger Neanderthals from Europe and western Asia.
The test could potentially enable labs to bring resistance testing in house, rather than send testing out to Canada's National Microbiology Laboratory.
A large genome-wide association meta-analysis and follow-up analyses revealed eight risk loci involving SNPs previously associated with body traits, metabolism, and psychiatric risk.
The assets include intellectual property relevant to iPSC-based phenotypic drug discovery and an existing product business around iPSC-derived cells.
Last week, GenomeWeb's readers were most interested in a story about a former Illumina employee who pleaded guilty to insider trading.
Of participants with high genetic risk, 1.13 percent with a favorable and 1.78 percent with an unfavorable lifestyle developed dementia over a median eight years.
The iC-GN Assay detects target DNA and identifies gram-negative organisms associated with gram-negative bacteremia, and three antibiotic-resistance markers.
Individuals with Alzheimer's disease are enriched for somatic mutations in brain tissue that affect tau-related pathways, as compared to unaffected individuals.
The company — develops tests for the early detection of cancer and other diseases in whole blood — is targeting C$3.7 million in a private placement financing round.
Invitae sees Jungla's AI platform as complementary to its own variant classification and interpretation methods.
The San Diego-based firm said it expects second quarter revenues of $835 million, short of the average analyst estimate of $888 million.
The partners will offer drug discovery services based on human induced pluripotent stem cells and cells derived from these.
The deals cover Native Antigen's native and recombinant viral and bacterial antigens, antibodies, and immunoassays in certain European and Asian markets.
Vermont-based BioTek is a privately held company that manufactures and sells life science instruments, including cell imaging systems.
The latest NYS Department of Health approval expands the company's CT/NG testing to samples from multiple relevant body sites.
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
A new analysis finds some cancers receive more nonprofit dollars than others.
An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.
In Science this week: comparative analysis of sex differences in mammal gene expression, and more.